Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193272 | 0.92 | BRAF (0.65) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL2193527 | 0.92 | BRAF (0.64) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL1727977 | 0.91 | BRAF (0.72) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL1726343 | 0.88 | BRAF (0.68) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL2192679 | 0.87 | BRAF (0.83) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL2190077 | 0.87 | BRAF (0.63) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL2191357 | 0.84 | BRAF (0.60) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL2197684 | 0.84 | BRAF (0.59) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL12350014 | 0.83 | BRAF (0.62) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL12508105 | 0.82 | BRAF (0.60) | BRAFLCKLYNTGFBR1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-12-29 | — | — | US | disclosed |
| WO-2010104899-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | STK24, MAP3K5, MAP3K2 | BRAF 76/4885LCK 49/4885LYN 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.